Our Services
Medical Information
Helpful Resources
Published on: 5/21/2026
Long-acting beta agonists (LABAs) are essential medications for managing asthma and COPD by relaxing airway muscles, improving breathing, and reducing flare-ups. However, LABAs carry important risks, including increased asthma-related events when used without inhaled corticosteroids, medication tolerance that reduces effectiveness over time, and potential cardiovascular side effects such as increased heart rate or blood pressure changes.
Key factors for safe LABA use include correct dosing, proper inhaler technique, combination therapy with inhaled steroids, and monitoring for warning signs like worsening symptoms or heart palpitations.
If you're experiencing breathing difficulties, wheezing, chronic cough, or other respiratory symptoms, understanding what's happening in your body is the critical first step toward effective treatment. Because asthma, COPD, and other respiratory conditions share overlapping symptoms but require very different treatment approaches, getting clarity early can help you avoid complications and have more productive conversations with your doctor. Take a free, instant, online symptom check to better understand your symptoms and confidently navigate your next steps.
Reviewed for medical accuracy: 07/09/2026
Long-acting beta-agonists (LABAs) are a cornerstone in the management of asthma and chronic obstructive pulmonary disease (COPD). When used correctly, they can greatly improve breathing, reduce symptoms, and lower the risk of flare-ups. However, like all medications, LABAs carry certain risks. This guide explains the science behind LABA risks in clear, common language—no sugar-coating, no panic.
LABAs are inhaled medicines that relax the muscles around your airways for up to 12 hours (sometimes 24 hours). By opening the airways, they help you breathe more easily. Common LABAs include formoterol and salmeterol.
When prescribed and used correctly, LABAs can:
These benefits are well supported by clinical trials and international guidelines.
Although LABAs are generally safe, certain risks deserve attention.
Most side effects are mild and manageable:
Certain factors can raise the chance of experiencing adverse effects:
If you experience any of the following, contact your healthcare provider promptly:
If you're unsure whether your respiratory symptoms require immediate medical attention, you can check your symptoms with Ubie's free AI-powered tool to get personalized insights in just minutes before deciding on your next steps.
Some signs may indicate a serious or life-threatening situation:
If you notice any of these, call emergency services or go to the nearest emergency department—and speak to a doctor right away.
Long-acting beta-agonists have transformed asthma and COPD care. Their benefits—fewer flare-ups, better lung function, improved daily life—are significant. Yet, like any powerful medicine, they must be used wisely to minimize risks.
If you're experiencing new or worsening breathing difficulties, medication side effects, or are simply concerned about changes in your respiratory health, take a moment to use Ubie's AI symptom checker for a quick, free assessment that can help you understand what might be happening and whether you should seek immediate care.
Your safety is paramount—never hesitate to get professional medical advice for anything that feels serious or life-threatening.
(References)
* Almadhoun K, Taha M, Al-Chalabi B, et al. Safety and efficacy of long-acting beta-agonists (LABAs) for asthma: An update. J Asthma. 2021 May;58(5):610-618. doi: 10.1080/02770903.2019.1704259. Epub 2020 Jan 2. PMID: 31893452.
* Matera MG, Rinaldi B, Rogliani P, Cazzola M. Long-Acting Beta-Agonists and Asthma Control: Current Evidence and Future Directions. J Clin Med. 2022 Mar 15;11(6):1618. doi: 10.3390/jcm11061618. PMID: 35329971; PMCID: PMC8950854.
* Cazzola M, Calzetta L, Rogliani P, Matera MG. Inhaled Corticosteroids/Long-acting β2-Agonists in Asthma: The Current Evidence on Safety. Curr Med Chem. 2018;25(16):1812-1823. doi: 10.2174/0929867324666170609090632. PMID: 28599691.
* Cazzola M, Matera MG, Rogliani P. Safety and efficacy of combined inhaled corticosteroids and long-acting β2-agonists in asthma and COPD. Expert Opin Drug Saf. 2017 Jul;16(7):781-791. doi: 10.1080/14740338.2017.1332857. Epub 2017 May 30. PMID: 28557436.
* Salpeter SR, Salpeter EE, Buckley NS, Thabane L, Sharma S, Nelson HS. Meta-analysis of trials of long-acting beta2-agonists in asthma: evidence of increased mortality. Respir Med. 2006 Jan;100(1):1-10. doi: 10.1016/j.rmed.2005.04.020. PMID: 16216480.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.